Cargando…
Neuroleptic Malignant Syndrome with Adrenal Insufficiency After BNT162b2 COVID-19 Vaccination in a Man Taking Valproate: A Case Report
Patient: Male, 48-year-old Final Diagnosis: Neuroleptic malignant syndrome Symptoms: Altered mental status • fatigue • fever • generalized weakness • loss of appetite Medication: — Clinical Procedure: — Specialty: Critical Care Medicine • Endocrinology and Metabolic • Neurology OBJECTIVE: Unusual cl...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087139/ https://www.ncbi.nlm.nih.gov/pubmed/35514081 http://dx.doi.org/10.12659/AJCR.936217 |
_version_ | 1784704138200743936 |
---|---|
author | Mizuno, Tomohito Takahashi, Riku Kamiyama, Takahiro Suzuki, Atsushi Suzuki, Masashi |
author_facet | Mizuno, Tomohito Takahashi, Riku Kamiyama, Takahiro Suzuki, Atsushi Suzuki, Masashi |
author_sort | Mizuno, Tomohito |
collection | PubMed |
description | Patient: Male, 48-year-old Final Diagnosis: Neuroleptic malignant syndrome Symptoms: Altered mental status • fatigue • fever • generalized weakness • loss of appetite Medication: — Clinical Procedure: — Specialty: Critical Care Medicine • Endocrinology and Metabolic • Neurology OBJECTIVE: Unusual clinical course BACKGROUND: Considering the ongoing coronavirus disease 2019 (COVID-19) pandemic, sufficient information about common and serious adverse events is needed to rapidly distribute COVID-19 vaccines worldwide. We report a case of neuroleptic malignant syndrome (NMS) with adrenal insufficiency after initial vaccination with Pfizer/BioNTech BNT162b2. CASE REPORT: A 48-year-old man presented to the Emergency Department with fever and an altered mental status 7 days after receiving the first dose of the BNT162b2 COVID-19 vaccine. The patient had a history of end-stage renal disease and epilepsy treated with valproate. He was diagnosed with NMS based on the clinical findings of hyperthermia, muscular rigidity, and an elevated creatine kinase level. Additionally, a reduction in the response of cortisol to adrenocorticotropic hormone (ACTH) stimulation was observed in the rapid ACTH stimulation test. The patient was treated with dantrolene, bromocriptine, and hydrocortisone, and he responded well to treatment. Dantrolene and bromocriptine were tapered off over 4 weeks. Hydrocortisone was also tapered, and the patient was discharged on oral hydrocortisone (30 mg). CONCLUSIONS: The present case suggests a possible link between the BNT162b2 COVID-19 vaccine and NMS with adrenal insufficiency based on the temporal relationship between vaccine administration and disease onset, although the patient was taking valproate, a potential cause of NMS. Having a high level of suspicion is important because the diagnosis of NMS with adrenal insufficiency is often challenging due to non-specific clinical manifestations. However, this case does not negate the utility of vaccination because these complications are extremely rare and can be treated with early diagnosis and proper management. |
format | Online Article Text |
id | pubmed-9087139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90871392022-06-08 Neuroleptic Malignant Syndrome with Adrenal Insufficiency After BNT162b2 COVID-19 Vaccination in a Man Taking Valproate: A Case Report Mizuno, Tomohito Takahashi, Riku Kamiyama, Takahiro Suzuki, Atsushi Suzuki, Masashi Am J Case Rep Articles Patient: Male, 48-year-old Final Diagnosis: Neuroleptic malignant syndrome Symptoms: Altered mental status • fatigue • fever • generalized weakness • loss of appetite Medication: — Clinical Procedure: — Specialty: Critical Care Medicine • Endocrinology and Metabolic • Neurology OBJECTIVE: Unusual clinical course BACKGROUND: Considering the ongoing coronavirus disease 2019 (COVID-19) pandemic, sufficient information about common and serious adverse events is needed to rapidly distribute COVID-19 vaccines worldwide. We report a case of neuroleptic malignant syndrome (NMS) with adrenal insufficiency after initial vaccination with Pfizer/BioNTech BNT162b2. CASE REPORT: A 48-year-old man presented to the Emergency Department with fever and an altered mental status 7 days after receiving the first dose of the BNT162b2 COVID-19 vaccine. The patient had a history of end-stage renal disease and epilepsy treated with valproate. He was diagnosed with NMS based on the clinical findings of hyperthermia, muscular rigidity, and an elevated creatine kinase level. Additionally, a reduction in the response of cortisol to adrenocorticotropic hormone (ACTH) stimulation was observed in the rapid ACTH stimulation test. The patient was treated with dantrolene, bromocriptine, and hydrocortisone, and he responded well to treatment. Dantrolene and bromocriptine were tapered off over 4 weeks. Hydrocortisone was also tapered, and the patient was discharged on oral hydrocortisone (30 mg). CONCLUSIONS: The present case suggests a possible link between the BNT162b2 COVID-19 vaccine and NMS with adrenal insufficiency based on the temporal relationship between vaccine administration and disease onset, although the patient was taking valproate, a potential cause of NMS. Having a high level of suspicion is important because the diagnosis of NMS with adrenal insufficiency is often challenging due to non-specific clinical manifestations. However, this case does not negate the utility of vaccination because these complications are extremely rare and can be treated with early diagnosis and proper management. International Scientific Literature, Inc. 2022-05-06 /pmc/articles/PMC9087139/ /pubmed/35514081 http://dx.doi.org/10.12659/AJCR.936217 Text en © Am J Case Rep, 2022 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Articles Mizuno, Tomohito Takahashi, Riku Kamiyama, Takahiro Suzuki, Atsushi Suzuki, Masashi Neuroleptic Malignant Syndrome with Adrenal Insufficiency After BNT162b2 COVID-19 Vaccination in a Man Taking Valproate: A Case Report |
title | Neuroleptic Malignant Syndrome with Adrenal Insufficiency After BNT162b2 COVID-19 Vaccination in a Man Taking Valproate: A Case Report |
title_full | Neuroleptic Malignant Syndrome with Adrenal Insufficiency After BNT162b2 COVID-19 Vaccination in a Man Taking Valproate: A Case Report |
title_fullStr | Neuroleptic Malignant Syndrome with Adrenal Insufficiency After BNT162b2 COVID-19 Vaccination in a Man Taking Valproate: A Case Report |
title_full_unstemmed | Neuroleptic Malignant Syndrome with Adrenal Insufficiency After BNT162b2 COVID-19 Vaccination in a Man Taking Valproate: A Case Report |
title_short | Neuroleptic Malignant Syndrome with Adrenal Insufficiency After BNT162b2 COVID-19 Vaccination in a Man Taking Valproate: A Case Report |
title_sort | neuroleptic malignant syndrome with adrenal insufficiency after bnt162b2 covid-19 vaccination in a man taking valproate: a case report |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087139/ https://www.ncbi.nlm.nih.gov/pubmed/35514081 http://dx.doi.org/10.12659/AJCR.936217 |
work_keys_str_mv | AT mizunotomohito neurolepticmalignantsyndromewithadrenalinsufficiencyafterbnt162b2covid19vaccinationinamantakingvalproateacasereport AT takahashiriku neurolepticmalignantsyndromewithadrenalinsufficiencyafterbnt162b2covid19vaccinationinamantakingvalproateacasereport AT kamiyamatakahiro neurolepticmalignantsyndromewithadrenalinsufficiencyafterbnt162b2covid19vaccinationinamantakingvalproateacasereport AT suzukiatsushi neurolepticmalignantsyndromewithadrenalinsufficiencyafterbnt162b2covid19vaccinationinamantakingvalproateacasereport AT suzukimasashi neurolepticmalignantsyndromewithadrenalinsufficiencyafterbnt162b2covid19vaccinationinamantakingvalproateacasereport |